Faricimab for South Asian patients with diabetic eye swelling
This trial tests a new eye injection called faricimab to treat diabetic macular edema (swelling in the back of the eye) in South Asian patients. The goal is to see how well it works, how long the effects last, and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are of South Asian origin (Indian, Pakistani, Bangladeshi, or Sri Lankan).
- You are 18 years or older.
- You have diabetes (type 1 or type 2).
- Your vision in the study eye is between 6/12 and 6/120 (on a standard eye chart).
- You have swelling in the center of the retina that is causing vision problems.
- You have not had laser treatment on the study eye in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests whether faricimab, an eye injection for certain eye conditions, affects kidney function in people with diabetes. It is for those with diabetic macular edema, wet age-related macular degeneration, or macular edema from a vein blockage, who are already taking kidney-protective medications.
This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.